FreeIn Brief MD Anderson and Innovent Biologics to develop anti-PD-1 therapy in rare cancers May 22, 2020Vol.46 No.21
COVID-19 & CancerFree A telesitevisit: Cancer center site visits go virtual amid COVID-19 pandemic May 22, 2020Vol.46 No.21By Matthew Bin Han Ong
Conversation with The Cancer LetterCOVID-19 & CancerFree Erin Kobetz: How Sylvester’s cancer outreach is used to monitor COVID-19 in Miami-Dade May 22, 2020Vol.46 No.21By Paul Goldberg
COVID-19 & CancerFree Funerals, church choirs, poultry plants fuel COVID-19 in rural Georgia—threatening Atlanta with a second spike May 22, 2020Vol.46 No.21By Alexandria Carolan
COVID-19 & CancerFreeGuest Editorial CCC19 bridging the knowledge gap for patients with COVID-19 and cancerFirst results to be heard at 2020 ASCO Annual Meeting May 22, 2020Vol.46 No.21By Rana R. McKay, Toni K. Choueiri, Brian I. Rini and Jeremy L. Warner
COVID-19 & CancerFreeGuest Editorial Let’s not form blue ribbon panels to study disparities in COVID-19 deathsInstead, let’s find the will to act May 22, 2020Vol.46 No.21By Robert A. Winn and Katherine Y. Tossas
Drugs & TargetsFree FDA approves Retevmo, first therapy for lung and thyroid cancers with RET gene alterations May 15, 2020Vol.46 No.20
Drugs & TargetsFree FDA approves Lynparza + bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers May 15, 2020Vol.46 No.20
